Aclarion (NASDAQ:ACON) & InnovAge (NASDAQ:INNV) Head-To-Head Comparison

Aclarion (NASDAQ:ACON) and InnovAge (NASDAQ:INNV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership.

Volatility and Risk

Aclarion has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, InnovAge has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.

Profitability

This table compares Aclarion and InnovAge’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,908.50%	-67.53%	-63.01%
InnovAge	0.71%	2.60%	1.23%

Earnings & Valuation

This table compares Aclarion and InnovAge”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$50,000.00	46.92	-$6.99 million	($15.00)	-0.18
InnovAge	$853.70 million	1.39	-$30.31 million	$0.05	174.60

Aclarion has higher earnings, but lower revenue than InnovAge. Aclarion is trading at a lower price-to-earnings ratio than InnovAge, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for Aclarion and InnovAge, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1	0	0	0	1.00
InnovAge	1	1	0	1	2.33

InnovAge has a consensus target price of $5.00, indicating a potential downside of 42.73%. Given InnovAge’s stronger consensus rating and higher probable upside, analysts clearly believe InnovAge is more favorable than Aclarion.

Insider and Institutional Ownership

7.5% of Aclarion shares are held by institutional investors. Comparatively, 12.3% of InnovAge shares are held by institutional investors. 0.8% of Aclarion shares are held by company insiders. Comparatively, 1.0% of InnovAge shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

InnovAge beats Aclarion on 11 of the 14 factors compared between the two stocks.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

About InnovAge

InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. The company serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.